Low Dose Antithymocyte Globulin (ATG) to Delay or Prevent Progression to Stage 3 T1D
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial
testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3
T1D.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)